Key result
Dynamic [18F]FLE-PET imaging detects markedly lower cardiac leucine uptake in hypertensive versus normotensive rats.
Why the study?
No clinically validated markers exist to identify hypertensive individuals at risk for developing LVH, prompting investigation into dynamic [18F]FLE-PET/CT to detect impaired cardiac leucine uptake as an early in vivo marker.
Does dynamic [18F]FLE-PET/CT imaging detect impaired cardiac leucine uptake in spontaneously hypertensive rats before LVH development?
Does dynamic [18F]FLE-PET/CT imaging detect impaired cardiac leucine uptake in spontaneously hypertensive rats before LVH development?
Dynamic [18F]FLE-PET imaging can detect decreased cardiac leucine uptake in hypertensive rats before the onset of left ventricular hypertrophy, suggesting its potential as an early in vivo marker of cardiometabolic dysfunction.
May support [18F]FLE-PET as an early marker of cardiometabolic dysfunction in hypertension; hypothesis-generating and requires human validation before clinical use.
Purpose Left ventricular hypertrophy (LVH) is a major complication of chronic hypertension and an independent risk factor for cardiovascular morbidity and mortality. There are currently no clinically validated markers available to identify hypertensive individuals at risk for developing LVH. In hearts of hypertensive rats, we previously described metabolic changes that precede LVH development, including in branched-chain amino acid (BCAA) metabolism. This study investigated whether cardiac leucine uptake, measured with dynamic 5-[ 18 F]fluoroleucine positron emission tomography-computed tomography ([ 18 F]FLE-PET/CT), was impaired and could serve as an in vivo marker for hypertension-induced LVH development. Procedures We synthesized [ 18 F]FLE following established radiochemistry protocols and performed dynamic [ 18 F]FLE-PET/CT imaging in 3-month-old spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) control rats (n = 4 per group). Cardiac magnetic resonance (CMR) imaging was conducted on the same animals for structural co-registration. A dual-output reversible two-tissue compartment model with spill-over (SP) and partial volume (PV) corrections was developed to quantify the first-pass rate constant (K 1 ) and total distribution volume (V t = K 1 /k 2 ) for [ 18 F]FLE. Protein expression of L-type amino acid transporter 1 (LAT1) and branched-chain keto acid dehydrogenase (BCKDH) phosphorylation status were assessed by immunoblotting of isolated heart tissue. Results SHR demonstrated markedly lower first-pass leucine uptake rates (K 1 ) and total distribution volumes (V t ) compared with WKY rats, consistent with reduced cardiac BCAA uptake. Concurrently, LAT1 (SLC7A5) expression was significantly reduced in SHR hearts compatible with decreased leucine uptake. Elevated BCKDH phosphorylation at Ser293 in SHR hearts indicated diminished BCKDH enzymatic activity and impaired BCAA catabolism. Conclusions Dynamic cardiac [ 18 F]FLE-PET imaging successfully detects decreased leucine uptake in hypertensive rat hearts at 3 months of age, before LVH is established at 5 months. Reduced cardiac leucine uptake may thus serve as a surrogate marker for impaired cardiac BCAA metabolism and early in vivo indicator of cardiometabolic dysfunction that precedes LVH. The imaging approach holds translational potential for identifying hypertensive patients at risk for LVH progression.
No takes yet. Share an insight, caveat, or question.
Terrell et al. (2026) studied Hypertension-induced left ventricular hypertrophy (n=8). Dynamic [18F]fluoroleucine PET/CT vs. Normotensive Wistar-Kyoto (WKY) control rats was evaluated on First-pass leucine uptake rates (K1) and total distribution volumes (Vt). Dynamic cardiac [18F]FLE-PET imaging detected markedly lower first-pass leucine uptake rates and total distribution volumes in hypertensive rats compared with normotensive controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: